Agitator to stimulate the central nervous system

Information

  • Patent Grant
  • 8579794
  • Patent Number
    8,579,794
  • Date Filed
    Friday, May 1, 2009
    15 years ago
  • Date Issued
    Tuesday, November 12, 2013
    11 years ago
Abstract
A tactile and audible sensation can be provided to a patient using a coiled or scrolled film in response to a received control signal. The tactile and audible sensation can be configured to stimulate the patient's central nervous system to sufficiently interrupt and undesirable sleep behavior of the patient, but avoid significantly changing a sleep state of the patient.
Description
TECHNICAL FIELD

This invention relates generally to the field of neurological disorders and more specifically to the area of sleep medicine and yet even more specifically to the area of sleep therapy for patients who suffer from sleep disorders such as obstructive sleep apnea, central sleep apnea, complex sleep apnea, restless leg syndrome (RLS), sudden infant death syndrome (SIDS) and related physiologic events or conditions occurring during sleep. More particularly, the present invention relates to a device for stimulating the central nervous system of a patient suffering from a sleep disorder.


BACKGROUND

Sleep disorders have recently become the focus of a growing number of physicians. Many hospitals and clinics have established sleep laboratories (sleep labs) to diagnose and treat sleep disorders. In the sleep laboratories, practitioners use instrumentation to monitor and record a patient's sleep states and behaviors during sleep. Practitioners rely on these recordings to diagnose patients and prescribe proper therapies.


Various undesirable behaviors can occur during sleep, such as snoring, apnea episodes, abnormal breathing episodes and the like. In certain examples, these and other undesirable behaviors can lead to insufficient amounts of sleep, fatigue, or in the case of SIDS, even death. Thus, efforts are being made to reduce or eliminate these undesirable behaviors.


SUMMARY

In an example, a tactile and audible sensation can be provided to a patient using a coiled or scrolled film in response to a received control signal. In certain examples, the tactile and audible sensation can be configured to stimulate the patient's central nervous system to sufficiently interrupt and undesirable sleep behavior of the patient, but avoid significantly changing a sleep state of the patient.


In other examples, an agitator device can include a coiled film within a housing, the housing being in contact with a sleep patient, wherein the coiled film is connected to a selective source of alternating current, which matches the resonant frequency of the film such that when activated the film rapidly expands and contracts creating a mechanical motion or vibration, which creates a tactile event which is detected by the central nervous system of the sleep patient and wherein undesired sleeping behavior is interrupted, but sleep states are not altered nor is the patient awakened. The film is further disclosed as a piezoelectric film or a polyvinylidene film with metalized opposing surfaces. Further disclosed is a central nervous system stimulation controller controlling the signal transmitted to the agitator device.


Various stimulation systems are available for altering undesirable behavior during sleeping. For example, several United States patents are directed toward treatment of snoring including U.S. Pat. No. 4,644,330 to Dowling, U.S. Pat. No. 4,788,533 to Mequignon, and U.S. Pat. No. 5,477,867 to Balkanyi. These patents rely on an “aversive audio stimulus,” a “sound stimulus,” and “acoustic signals,” respectively.


As another example, in U.S. Pat. No. 3,802,417 to Lang, an alarm relay is triggered if a desired standard respiratory frequency is not attained. When triggered, the alarm relay switches on a respiration stimulator that consists of a rhythmically inflatable belt or cuff.


As an additional example, U.S. Pat. No. 4,715,367 to Crossley discloses a device to diagnose, treat and monitor treatment for snoring, bruxism, or sleep apnea. Here, treatment consists of a regulatable aversive shock.


As an additional example, U.S. Pat. No. 6,093,158 to Morris discloses monitoring an undesired behavioral disorder such as bruxism, jaw clenching, or snoring. Here, an alert system is selected from a group consisting of light controllers, temperature regulators, odor generators, high frequency generators, tactile pressure generators, vibratory generators, and electric current generators.


Further yet, U.S. Pat. No. 6,935,335 to Lehrman et al. discloses creating a stimulus to a person's neck muscles to cause said person to move said person's neck muscles to move said person's head backwards to terminate said physiological process before cessation of breathing occurs. The stimulus includes a vibrator and a sound generator placed adjacent to said person's neck muscles. Additional examples can be found in U.S. Patent Publication No. US 2003/0,195,588 to Fischell et al. and US 2008/0,009,915 to Moses et al.


The goal of addressing sleeping disorders is often to help a person sleep better. Several states of sleep exist and involve varying levels of consciousness, and the beneficial effects of sleep improve when it is uninterrupted. To the extent that devices above alter a patient's sleep state, or in a worst case scenario actually awaken a patient, the devices have gone too far. While they may have stopped the undesirable behavior, they have not helped a person sleep better.


In light of this very fine line between interrupting an undesirable behavior and altering a sleep state, there are several problems associated with the above devices. First, in the case of the audio, light, or odor devices, a vast range of patient sensitivities exist for each of these stimuli. Thus, these devices can have difficulty simultaneously altering an undesirable behavior and avoiding alteration of a sleep state because they are often under or over effective at stimulating a patient. Second, the inflatable belt or cuff and the temperature regulator both involve a certain ramp up and shut down time. This can make it difficult to precisely dose a patient when trying to stimulate the patient at the instant an undesirable behavior starts and to stop stimulation at the instant the behavior stops. Third, regarding the electric current and aversive shock, many people simply are not comfortable with the nature of this treatment. Fourth, vibration can work fairly universally, however, due to the inertial forces involved, the devices tend to have the same shut down problems mentioned above. That is, once the undesirable behavior stops and the device is switched off, it takes time for the vibration to stop and thus stop stimulating the patient. This can lead to over stimulation and an alteration in the patient's sleep state.


The present inventor has realized, among other things, that there is a need to provide an apparatus and method that stimulates the central nervous system sufficiently to interrupt an undesirable sleep behavior by a means universally sensed by most patients where the device avoids significantly changing sleep states and avoids waking a patient. Moreover, there is a need for this apparatus to be precisely controllable so as to provide precise doses of stimulation to a sleep disorder patient. There is also a need to provide an apparatus that is comfortable to wear so as to further its ability to avoid alteration of sleep states.


Certain embodiments of the present invention provide a piezoelectric agitation device that, by means of piezoelectric to mechanical motion conversion, provides stimulation of the central nervous system in general and to the human central nervous system in specific by means of tactical stimulation, by means of audible stimulation, or by both tactile and audio stimulation.


In one embodiment, a small strip of metalized piezoelectric film, preferably of either series or parallel bimorphic structure with wire terminals attached to opposing metalized surfaces of the film, has a coil, scroll, or barrel shape and is situated within a small plastic, glass, metal, or composite housing.


In another embodiment, a small strip of polyvinylidene fluoride film, with wire terminals attached to opposing metalized surfaces, has the shape of a loosely rolled scroll and is situated within a housing.


In Example 1, an agitator device for stimulating a central nervous system of a patient suffering from a sleep disorder includes a housing sized and shaped to fit within, on, around, or behind an ear of the patient, a film within the housing, the film configured to receive a control signal and to provide a tactile and audible sensation to the patient in response to the received control signal, the tactile and audible sensation configured to stimulate the patient's central nervous system to sufficiently interrupt an undesirable sleep behavior of the patient, but avoid significantly changing a sleep state of the patient.


In Example 2, the film of Example 1 optionally includes a coiled or scrolled polyvinylidene fluoride (PVDF) film.


In Example 3, the PVDF film of any one or more of Examples 1-2 optionally includes a metalized PVDF film having at least one of a series or parallel bimorphic structure.


In Example 4, the housing of any one or more of Examples 1-3 is optionally configured to fit within the ear.


In Example 5, the control signal of any one or more of Examples 1-4 optionally includes an alternating current (AC) excitation voltage control signal configured to control expansion and contraction of the film according to an instantaneous voltage polarity of the control signal, causing the film to vibrate, the vibration providing the tactile and audible sensation.


In Example 6, the frequency of the control signal of any one or more of Examples 1-5 is optionally configured to substantially match a resonant frequency of the film to provide a desired efficiency of the tactile and audible sensation.


In Example 7, the frequency of the control signal of any one or more of Examples 1-6 optionally includes a frequency between 1 Hz and 100 Hz.


In Example 8, a system for stimulating a central nervous system of a patient suffering from a sleep disorder includes a sleep sensor configured to receive sleep information from the patient, an agitator including a housing sized and shaped to fit within, on, around, or behind an ear of the patient and a film within the housing, the film configured to provide a tactile and audible sensation to the patient, the tactile and audible sensation configured to stimulate the patient's central nervous system, and a controller configured to receive sleep information from the sleep sensor, to produce a control signal for the agitator using the received sleep information, and to provide the control signal to the to the agitator, the control signal configured to control the tactile and audible sensation of the agitator to sufficiently interrupt an undesirable sleep behavior of the patient, but avoid significantly changing a sleep state of the patient.


In Example 9, the sleep sensor of Example 8 optionally includes a respiration sensor configured to receive respiration information from the patient.


In Example 10, the sleep sensor of any one or more of Examples 8-9 optionally includes a sleep state sensor configured to receive information indicative of a sleep state of the patient.


In Example 11, the film of any one or more of Examples 8-10 optionally includes a coiled or scrolled metalized polyvinylidene fluoride (PVDF) film having at least one of a series or parallel bimorphic structure.


In Example 12, the housing of any one or more of Examples 8-11 is optionally configured to be affixed behind the ear using an adhesive.


In Example 13, the controller of any one or more of Examples 8-13 is optionally configured to produce an alternating current (AC) excitation voltage control signal to control expansion and contraction of the film according to an instantaneous voltage polarity of the control signal, causing the film to vibrate, the vibration providing the tactile and audible sensation, and wherein the frequency of the AC excitation voltage control signal is configured to substantially match a resonant frequency of the film to provide a desired efficiency of the tactile and audible sensation.


In Example 14, a method for stimulating a central nervous system of a patient suffering from a sleep disorder includes receiving a control signal from a controller and providing a tactile and audible sensation to the patient using a coiled or scrolled film in response to the received control signal, the tactile and audible sensation configured to stimulate the patient's central nervous system to sufficiently interrupt an undesirable sleep behavior of the patient, but avoid significantly changing a sleep state of the patient.


In Example 15, the method of Example 14 optionally includes receiving sleep information from a patient, the sleep information including at least one of respiration information of the patient from a respiration sensor or information indicative of a sleep state of the patient from a sleep state sensor, and producing the control signal using the received sleep information.


In Example 16, the receiving the sleep information from the patient of any one or more of Examples 14-15 optionally includes receiving the respiration information of the patient from the respiration sensor.


In Example 17, the providing the tactile and audible sensation to the patient using the coiled or scrolled film includes using a metalized polyvinylidene fluoride (PVDF) film having at least one of a series or parallel bimorphic structure.


In Example 18, the method of any one or more of Examples 14-17 optionally includes providing a housing sized and shaped to fit within, on, around, or behind an ear of the patient, the housing including the coiled or scrolled film.


In Example 19, the method of any one or more of Examples 14-18 optionally includes producing an alternating current (AC) excitation voltage control signal to control expansion and contraction of the coiled or scrolled film according to an instantaneous voltage polarity of the control signal.


In Example 20, the producing the AC excitation voltage control signal of any one or more of Examples 14-19 optionally includes at a frequency configured to substantially match a resonant frequency of the coiled or scrolled film to provide a desired efficiency of the provided tactile and audible sensation.


While the present disclosure is directed toward treatment of sleep disorders, further areas of applicability will become apparent from the description provided herein. It should be understood that the description and specific examples are intended for purposes of illustration only and are not intended to limit the scope of the present disclosure.





DESCRIPTION OF THE DRAWINGS

The forgoing features, objects and advantages of the invention will become apparent to those skilled in the art from the following detailed description, especially when considered in conjunction with the accompanying drawings in which like the numerals in the several views refer to the corresponding parts:



FIG. 1 illustrates generally an example of a system including an agitator.



FIG. 2 illustrates generally an example of an agitator.



FIG. 3 illustrates generally an example of a cross-sectional view of an agitator.



FIG. 4 illustrates generally an example of a rolled out (unscrolled) film.



FIG. 5 illustrates generally an example of an agitator along with a housing containing a loosely coiled or scrolled up film.



FIG. 6 illustrates generally an example of a block diagram of an electrical control circuit for producing a control signal for an agitator.



FIG. 7 illustrates generally an example of a high-energy piezoelectric agitator control waveform pair.



FIG. 8 illustrates generally an example of a low-energy piezoelectric agitator control waveform pair.





DETAILED DESCRIPTION

The following detailed description relates to an agitator directed toward treating patients with sleep disorders in sleep laboratories. The agitator is more particularly directed at stimulating a patient to interrupt and terminate an undesired sleep behavior or condition such as snoring, sleep apnea, sudden infant death syndrome (SIDS) and others. The agitator may be used in conjunction with a sensor affixed to a patient and a controller. The sensor transmits respiratory information to a controller that analyzes the information and may trigger the agitator depending on the information received.


The following detailed description includes discussion of sensors affixed to patients, controllers, and agitators. Additionally, elements of an agitator are discussed including a housing, a film, and wire terminations. Controller circuitry, a bridge amplifier, and a power supply are also discussed. Information regarding the wave form generated by the bridge amplifier is also included.


The present invention can be readily understood from FIGS. 1 through 8.



FIG. 1 illustrates generally an example of a system including an agitator 6. In an example, a sleep therapy patient 1 suffering from a sleep disorder can be outfitted with a sensor 2 to measure respiratory effort. A pair of sensor output wire leads 3 connects the sensor to the input of the controller device 4. The output of the controller 4 connects via a pair of wire leads 5 to the agitator 6.


In an example, the sensor 2 of FIG. 1 can include a piezoelectric sensor constructed in accordance with the teachings of U.S. Pat. Nos. 5,311,875 and 6,254,545 to Stasz, the teachings of which are hereby incorporated by reference. Those skilled in the art will understand and appreciate that various sensors are known including, but not limited to thermistors, air pressure transducers, respiratory plethysmography inductance (RIP) belts, microphones, or one or more other sleep sensors, and that these sensors are within the scope of the present subject matter.


In an example, the controller shown in FIG. 1 can include a Central Nervous System Stimulation Controller. Those skilled in the art will understand and appreciate that various controllers exist for monitoring patients, analyzing information, and transmitting a signal to another device based on that information.



FIG. 2 illustrates generally an example of an agitator 6. In this example, there is indicated generally an agitator 6 along with a housing 10 containing a coiled or scrolled film 20. Attached to each surface of the film are wire terminations 30 and 40 via which the agitator receives the output from the controller and these devices are thus within the scope of the present invention.



FIG. 3 illustrates generally an example of a cross-sectional view of an agitator 6. In this example, there is indicated generally an agitator 6 along with housing 10 containing a coiled or scrolled film 20. Attached to each side of the film are the wire terminations 30 and 40 via which the agitator is connected to the controller.



FIG. 4 illustrates generally an example of a rolled out (unscrolled) film 20. Those skilled in the art will understand and appreciate that various lengths and widths of film are within the scope and spirit of the invention. The width and length can be varied based on several factors including but not limited to, the size of the device, the desired looseness of the fit of the film in the housing, and the desired level of agitation.



FIG. 5 illustrates generally an example of an agitator 6 along with a housing 10 containing a loosely coiled or scrolled up film 20. Attached to each side of the film are wire terminations 30 and 40 via which the agitator 6 is connected to a controller.


In an example, the film shown in FIGS. 2-5 can include a piezoelectric film. More particularly, the film can include a polyvinylidene fluoride (PVDF) film. In certain examples, the PVDF film can be a metalized PVDF film of either series or parallel bimorphic structure. Those skilled in the art will understand and appreciate the piezoelectric to mechanical motion conversion properties of PVDF. However, other films known in the art which have mechanical motion conversion properties are within the scope of the invention. While the film is shown to be scrolled in the shape of a cylindrical coil, other shapes including square or triangular are within the scope of the invention.


The housing shown in FIGS. 2-5 can include a plastic, metal, glass, or composite material. In an example, the housing can be light weight so as to minimize the momentum associated with its motion. The housing could be any size and is not limited in size to use in conjunction with the human body. Moreover, the shape of the housing can vary and is not limited to a cylindrical shape. Other shapes including rectangular, triangular, or polygon shapes adapted for a specific purpose are within the scope of the invention. In an example, the shape of the housing may be adapted to fit within, on, around, or behind the ear similar to that of a hearing aid or ear bud. In other examples, the housing can be adapted to be fixed in, on, behind, or around the ear (e.g., using an adhesive).


In application, a controller can transmit an alternating current (AC) excitation voltage via wire terminations 30 and 40 to the opposing metalized surfaces of a PVDF film. The inherent characteristics of the loosely rolled piezoelectric film can cause it to expand and contract according to the instantaneously applied voltage polarity of the excitation signal, thus causing the film to vibrate. In an example, the frequency of the AC can match the resonance frequency of the coiled structure of the agitator thus minimizing the required electrical power and maximizing the resulting mechanical force. The AC current frequency, while not limited to this range, may fall in the range of 1 Hz to 100 Hz.


The resulting mechanical motion or vibration of the film can be transferred to the housing of the agitator which can creates both a tactile and audible sensation. This mechanical motion or vibration is passed subsequently on to the hairs and skin of the patient that the agitator is in contact with. This transfer of mechanical motion or vibration to the skin and hairs of the patient creates a tactile event which is detected by the central nervous system.


In one embodiment, as mentioned above, the housing can be in the shape of an ear bud for placement in a patient's ear. In this embodiment, the agitator creates a sensation comparable to an insect moving around quickly and briefly in the ear canal.


In an example embodiment, the stimulation of the agitator can be sufficient to cause a sleeping patient to interrupt an undesirable sleeping behavior, but is not sufficient to alter the sleep state of the patient. Thus, depending on the condition being treated, the patient can stop snoring, or start breathing without alteration of the patient's sleep state.


The nature of the thin film and light weight housing allows the device to maintain a low momentum even at high velocity. Thus, the ramp up and shut down period required for this device is almost instantaneous. When the AC excitation voltage is transmitted, the device immediately begins its mechanical motion or vibration and when the AC excitation voltage stops, the device immediately stops. This is because the momentum of the device, while moving very quickly, is small, because of its low mass. This is in contrast to well known vibratory devices in cell phones and pagers, where the mass of the devices is quite large relative to the agitator disclosed herein.



FIG. 6 illustrates generally an example of a block diagram of an electrical control circuit for producing a control signal for an agitator 6. In this example, the controller circuitry 50 is configured to issue the precisely dosed control signal for further processing in a typical high voltage bridge amplifier 60. In this example, the bridge amplifier 60 is powered by the power supply 70. The bridge amplifier 60 connects to the agitator 6 via the electrical wire pairs 30 and 40.


In one embodiment, the power supply 70 is a typical electrical power outlet. In another embodiment, the power supply is battery power. In yet another embodiment, as discussed in more detail below, the power supply for the controller is separate from the power supply for the agitator. In this embodiment, the power supply for each of them could be an electrical outlet or battery power.



FIG. 7 illustrates generally an example of a high-energy piezoelectric agitator control waveform pair 32 and 42. In an example, the high-energy piezoelectric agitator control waveform pair 32 and 42 can be generated by the bridge amplifier 60 and carried to a piezoelectric agitator via the wire leads 30 and 40.



FIG. 8 illustrates generally an example of a low-energy piezoelectric agitator control waveform pair 34 and 44. In an example, the low-energy piezoelectric agitator control waveform pair 34 and 44 can be generated by the bridge amplifier 60 and carried to a piezoelectric agitator via the wire leads 30 and 40.


The energy of the waveform results in higher and lower levels of vibration magnitude. Those skilled in the art will understand and appreciate that various waveforms are available and the two shown are merely exemplary. Alternative waveforms include, but are not limited to, sinusoidal, square, trapezoidal, triangular, and sawtooth.


In one embodiment, a wireless agitator includes a housing, a receiver, a power supply, and a film located within the housing. During application, the receiver receives a remote signal from a controller and sends the signal to the film via wire terminations. The receiver is powered by the power supply. In an alternative embodiment, the remotely controlled agitator also includes a controller and may further include a bridge amplifier. In this embodiment, the receiver can receive a signal from either a transmitter on the patient sensor or from a transmitter connected to the patient sensor. In either case, the receiver can transmit the signal to the controller which in turn can transmit the signal to the bridge amplifier. As with the above embodiments, a waveform can then be transmitted to the film creating mechanical movement of the agitator.


The present inventor has realized, among other things, that an agitator can be directed toward transfer of mechanical energy to create a tactile sensation, which makes the device universally effective for most sleep patients. This is in contrast to the sound, light, and odor type devices of the prior art.


An additional advantage of the present invention is the precision with which stimulating doses can be given to a sleep patient. Due to the light weight nature of the device and its electrical activation, the device can be started and stopped extremely quickly thus stimulating the central nervous system in very specific and defined doses. This contributes to its ability to interrupt an undesired behavior and yet avoid altering the patients' sleep state.


Another advantage of the present invention relating to its light weight is the ability to cause large magnitude mechanical motion with very little electrical power simply by stimulating the device with an alternating current matching its resonant frequency. This advantage makes it possible for the device to be supplied with battery power and sustain battery life for an extended period of time.


This leads to an additional advantage. The device's ability to operate on battery power can allow the device to operate remotely, thus eliminating the need for wire leads and positive electrical connections to a controller. Thus, the device can be placed in the ear much like a hearing aid and be worn very comfortably by a sleep patient. This further supports the device's ability to interrupt an undesirable behavior while avoiding alteration of a sleep state.


This invention has been described herein in considerable detail in order to comply with the patent statutes and to provide those skilled in the art with the information needed to apply the novel principles and to construct and use such specialized components as are required. However, it is to be understood that the invention can be carried out by specifically different equipment and devices, and that various modifications, both as to the equipment and operating procedures, can be accomplished without departing from the scope of the invention itself.


The description of the various embodiments is merely exemplary in nature and, thus, variations that do not depart from the gist of the examples and detailed description herein are intended to be within the scope of the present disclosure. Such variations are not to be regarded as a departure from the spirit and scope of the present disclosure.

Claims
  • 1. A method for stimulating a central nervous system of a patient suffering from a sleep disorder, comprising: receiving a control signal from a controller;transferring a mechanical vibration of a coiled or scrolled film to a housing, sized and shaped to fit within, on, around, or behind an ear of the patient, in response to the received control signal, wherein the housing includes the coiled or scrolled film; andpassing a tactile and audible sensation to the patient using the housing, the tactile and audible sensation configured to stimulate the patient's central nervous system to interrupt an undesirable sleep behavior of the patient, but avoid changing a sleep state of the patient.
  • 2. The method of claim 1, including: receiving sleep information from a patient, the sleep information including at least one of: respiration information of the patient from a respiration sensor; orinformation indicative of a sleep state of the patient from a sleep state sensor; andproducing the control signal using the received sleep information.
  • 3. The method of claim 2, wherein the receiving the sleep information from the patient includes receiving the respiration information of the patient from the respiration sensor.
  • 4. The method of claim 1, wherein the transferring a mechanical vibration of the coiled or scrolled film includes using a metalized polyvinylidene fluoride (PVDF) film having at least one of a series or parallel bimorphic structure.
  • 5. The method of claim 1, including producing an alternating current (AC) excitation voltage control signal to control expansion and contraction of the coiled or scrolled film according to an instantaneous voltage polarity of the control signal.
  • 6. The method of claim 5, wherein the producing the AC excitation voltage control signal includes producing the AC excitation voltage control signal at a frequency configured to match a resonant frequency of the coiled or scrolled film to provide a desired efficiency of the provided tactile and audible sensation.
  • 7. The method of claim 1, wherein the film includes a coiled or scrolled polyvinylidene fluoride (PVDF) film.
  • 8. The method of claim 7, wherein the PVDF film includes a metalized PVDF film having at least one of a series or parallel bimorphic structure.
  • 9. The method of claim 1, wherein the film includes a coiled film.
  • 10. The method of claim 1, wherein the film includes a scrolled film.
  • 11. The method of claim 1, wherein the housing is sized and shaped to fit within the ear.
CLAIM OF PRIORITY

This patent application claims the benefit of priority to U.S. Provisional Patent Application Ser. No. 61/049,802, filed on May 2, 2008, which application is herein incorporated by reference in its entirety.

US Referenced Citations (225)
Number Name Date Kind
3478344 Schwitzgebel et al. Nov 1969 A
3483861 Tiep Dec 1969 A
3530494 Baratta Sep 1970 A
3572316 Vogelman et al. Mar 1971 A
3593703 Gunn et al. Jul 1971 A
3696377 Wall Oct 1972 A
3782368 Reibold Jan 1974 A
3802417 Lang Apr 1974 A
3827301 Parker Aug 1974 A
3998209 Macvaugh Dec 1976 A
4072145 Silva Feb 1978 A
4169462 Strube Oct 1979 A
4185621 Morrow Jan 1980 A
4220142 Rosen et al. Sep 1980 A
4267845 Robertson, Jr. et al. May 1981 A
4304227 Samelson Dec 1981 A
4308872 Watson et al. Jan 1982 A
4373534 Watson Feb 1983 A
4378808 Lichtenstein Apr 1983 A
4440160 Fischell et al. Apr 1984 A
4443730 Kitamura et al. Apr 1984 A
4452252 Sackner Jun 1984 A
4456015 Sackner Jun 1984 A
4499394 Koal Feb 1985 A
4503862 Baessler Mar 1985 A
4509527 Fraden Apr 1985 A
4576179 Manus et al. Mar 1986 A
4577510 Bur et al. Mar 1986 A
4593686 Lloyd et al. Jun 1986 A
4600855 Strachan Jul 1986 A
4644330 Dowling Feb 1987 A
4666198 Heiserman May 1987 A
4669477 Ober Jun 1987 A
4700203 Yamamuro et al. Oct 1987 A
4715367 Crossley Dec 1987 A
4747413 Bloch May 1988 A
4748672 Nevill, Jr. et al. May 1988 A
4788533 Mequignon Nov 1988 A
4791933 Asai et al. Dec 1988 A
4813427 Schlaefke et al. Mar 1989 A
4814661 Ratzlaff et al. Mar 1989 A
4817625 Miles Apr 1989 A
4819860 Hargrove et al. Apr 1989 A
4823802 Romanovskaya Apr 1989 A
4827943 Bornn et al. May 1989 A
4830008 Meer May 1989 A
4834109 Watson May 1989 A
4836219 Hobson et al. Jun 1989 A
4895160 Reents Jan 1990 A
4909260 Salem et al. Mar 1990 A
4958645 Cadell et al. Sep 1990 A
4960118 Pennock Oct 1990 A
4971065 Pearce Nov 1990 A
4986277 Sackner Jan 1991 A
4989612 Fore Feb 1991 A
5038785 Blakeley et al. Aug 1991 A
5069221 Smith et al. Dec 1991 A
5088501 Niewisch Feb 1992 A
5099702 French Mar 1992 A
5113566 Weekamp et al. May 1992 A
5123425 Shannon, Jr. et al. Jun 1992 A
5161541 Bowman et al. Nov 1992 A
5178156 Takishima et al. Jan 1993 A
5201322 Henry et al. Apr 1993 A
5207230 Bowers May 1993 A
D338413 Ciambella Aug 1993 S
5277193 Takishima et al. Jan 1994 A
5295490 Dodakian Mar 1994 A
5311875 Stasz May 1994 A
5329931 Clauson et al. Jul 1994 A
5331968 Williams et al. Jul 1994 A
5335657 Terry, Jr. et al. Aug 1994 A
5348008 Bornn et al. Sep 1994 A
5365937 Reeves et al. Nov 1994 A
5413111 Wilkinson May 1995 A
5477867 Balkanyi Dec 1995 A
5515738 Tamori May 1996 A
5540733 Testerman et al. Jul 1996 A
5549655 Erickson Aug 1996 A
5555891 Eisenfeld Sep 1996 A
5558099 Bowman et al. Sep 1996 A
5748103 Flach et al. May 1998 A
5762583 Adams et al. Jun 1998 A
5765563 Schaaf Jun 1998 A
5767791 Stoop et al. Jun 1998 A
5797849 Vesely et al. Aug 1998 A
5825119 Shibata et al. Oct 1998 A
5825293 Ahmed et al. Oct 1998 A
5827198 Kassal Oct 1998 A
5832592 Bowman et al. Nov 1998 A
5853005 Scanlon Dec 1998 A
D410584 Stasz et al. Jun 1999 S
5913815 Ball et al. Jun 1999 A
5913829 Reeves et al. Jun 1999 A
5924979 Swedlow et al. Jul 1999 A
5963650 Simionescu et al. Oct 1999 A
D417161 Stasz et al. Nov 1999 S
5996418 Rector et al. Dec 1999 A
6004269 Crowley et al. Dec 1999 A
6070098 Moore-Ede et al. May 2000 A
6091973 Colla et al. Jul 2000 A
6093158 Morris Jul 2000 A
6142950 Allen et al. Nov 2000 A
6185452 Schulman et al. Feb 2001 B1
6213942 Flach et al. Apr 2001 B1
6213955 Karakasoglu et al. Apr 2001 B1
6240316 Richmond et al. May 2001 B1
6240323 Calenzo, Sr. et al. May 2001 B1
6251126 Ottenhoff et al. Jun 2001 B1
6254545 Stasz et al. Jul 2001 B1
6269269 Ottenhoff et al. Jul 2001 B1
6287264 Hoffman Sep 2001 B1
6306088 Krausman et al. Oct 2001 B1
6341230 Koike et al. Jan 2002 B1
6345202 Richmond et al. Feb 2002 B2
6363270 Colla et al. Mar 2002 B1
6368287 Hadas Apr 2002 B1
6383143 Rost May 2002 B1
6456887 Dudding et al. Sep 2002 B1
6485432 Stasz et al. Nov 2002 B1
6491642 Stasz Dec 2002 B1
6496705 Ng et al. Dec 2002 B1
6544192 Starr et al. Apr 2003 B2
6544199 Morris Apr 2003 B1
6551256 Stasz et al. Apr 2003 B1
6561987 Pail May 2003 B2
6702755 Stasz et al. Mar 2004 B1
6734802 Halleck et al. May 2004 B2
6762687 Perlman Jul 2004 B2
6811538 Westbrook et al. Nov 2004 B2
6840907 Brydon Jan 2005 B1
6894427 Alfini May 2005 B2
6935335 Lehrman et al. Aug 2005 B1
7007177 Cannon et al. Feb 2006 B2
7089932 Dodds Aug 2006 B2
7115097 Johnson Oct 2006 B2
7134435 Scott Nov 2006 B2
7206639 Jacobsen et al. Apr 2007 B2
7267652 Coyle et al. Sep 2007 B2
7277749 Gordon et al. Oct 2007 B2
7322356 Critzer et al. Jan 2008 B2
7336991 Yanagihara et al. Feb 2008 B2
7363926 Pflueger et al. Apr 2008 B2
7367935 Mechlenburg et al. May 2008 B2
7422014 Smith Sep 2008 B1
7426412 Schecter Sep 2008 B1
7427270 Izumi et al. Sep 2008 B2
7524279 Auphan Apr 2009 B2
20010018547 Mechlenburg et al. Aug 2001 A1
20020057202 Luzon May 2002 A1
20020123692 Pail Sep 2002 A1
20030100843 Hoffman May 2003 A1
20030187356 Wakabayashi et al. Oct 2003 A1
20030195588 Fischell et al. Oct 2003 A1
20030236467 Alfini Dec 2003 A1
20040039419 Stickney et al. Feb 2004 A1
20040113771 Ozaki et al. Jun 2004 A1
20040182386 Meier Sep 2004 A1
20040193003 Mechlenburg et al. Sep 2004 A1
20050061315 Lee et al. Mar 2005 A1
20050113646 Sotos et al. May 2005 A1
20050124864 Mack et al. Jun 2005 A1
20050137464 Bomba Jun 2005 A1
20050261559 Mumford et al. Nov 2005 A1
20060000472 Fenton Jan 2006 A1
20060034348 Schaefer et al. Feb 2006 A1
20060069320 Wolff et al. Mar 2006 A1
20060102171 Gavish May 2006 A1
20060145878 Lehrman et al. Jul 2006 A1
20060206014 Ariav Sep 2006 A1
20060212273 Krausman et al. Sep 2006 A1
20060212745 Zansky et al. Sep 2006 A1
20060214507 Suzuki Sep 2006 A1
20060241708 Boute Oct 2006 A1
20060283446 Chua et al. Dec 2006 A1
20070012089 Stasz Jan 2007 A1
20070016089 Fischell et al. Jan 2007 A1
20070049842 Hill et al. Mar 2007 A1
20070123758 Miesel et al. May 2007 A1
20070129644 Richards et al. Jun 2007 A1
20070131231 Sharp Jun 2007 A1
20070154022 Iketani et al. Jul 2007 A1
20070161903 Yamashita et al. Jul 2007 A1
20070172029 Felmlee et al. Jul 2007 A1
20070249952 Rubin et al. Oct 2007 A1
20070255161 De Backer Nov 2007 A1
20070282212 Sierra et al. Dec 2007 A1
20070282215 Ni et al. Dec 2007 A1
20080009915 Moses et al. Jan 2008 A1
20080021506 Grocela Jan 2008 A1
20080035158 Pflueger et al. Feb 2008 A1
20080066753 Martin et al. Mar 2008 A1
20080082018 Sackner et al. Apr 2008 A1
20080092898 Schneider et al. Apr 2008 A1
20080103407 Bolea et al. May 2008 A1
20080103545 Bolea et al. May 2008 A1
20080221468 Stahmann et al. Sep 2008 A1
20080234780 Smith et al. Sep 2008 A1
20080236597 Bergersen Oct 2008 A1
20080243014 Moussavi et al. Oct 2008 A1
20080243017 Moussavi et al. Oct 2008 A1
20080243023 Valkhof et al. Oct 2008 A1
20080275356 Stasz et al. Nov 2008 A1
20090050154 Strothmann et al. Feb 2009 A1
20090076405 Amurthur et al. Mar 2009 A1
20090158425 Chan et al. Jun 2009 A1
20090306528 Curti et al. Dec 2009 A1
20100048985 Henke et al. Feb 2010 A1
20100048986 Henke et al. Feb 2010 A1
20100049264 Henke et al. Feb 2010 A1
20100049265 Henke et al. Feb 2010 A1
20100056852 Henke et al. Mar 2010 A1
20100056853 Henke et al. Mar 2010 A1
20100056855 Henke et al. Mar 2010 A1
20100056941 Henke et al. Mar 2010 A1
20100056942 Henke et al. Mar 2010 A1
20100057148 Henke et al. Mar 2010 A1
20100063348 Henke et al. Mar 2010 A1
20100063350 Henke et al. Mar 2010 A1
20100069769 Henke et al. Mar 2010 A1
20100069771 Henke et al. Mar 2010 A1
20100069772 Henke et al. Mar 2010 A1
20100069773 Henke et al. Mar 2010 A1
20100076251 Stasz Mar 2010 A1
20100076252 Henke et al. Mar 2010 A1
Foreign Referenced Citations (18)
Number Date Country
0014693 Jun 1983 EP
0171321 Feb 1986 EP
1745742 Jan 2007 EP
WO-9705824 Feb 1997 WO
WO-0143804 Jun 2001 WO
WO-03022149 Mar 2003 WO
WO-03082108 Oct 2003 WO
WO-2004112606 Dec 2004 WO
WO-2006066337 Jun 2006 WO
WO-2006116469 Nov 2006 WO
WO-2007008706 Jan 2007 WO
WO-2007071180 Jun 2007 WO
WO-2008037820 Apr 2008 WO
WO-09134434 Nov 2009 WO
WO-2010021730 Feb 2010 WO
WO-2010030909 Mar 2010 WO
WO-2010033819 Mar 2010 WO
WO-2010033849 Mar 2010 WO
Non-Patent Literature Citations (54)
Entry
“Application Serial No. 09739237.7 Amended Claims Respnse filed Mar. 31, 2011”, 12 pgs.
“European Application Serial No. 09739237.7, Examination Notification Art. 94(3) mailed Jun. 20, 2011”, 5.
“International Application Serial No. PCT/US2009/002705, Search Report mailed Oct. 1, 2009”.
“International Application Serial No. PCT/US2009/002705, Written Opinion mailed Oct. 1, 2009”.
“U.S. Appl. No. 12/583,589, Response filed Apr. 5, 2012 to Restriction Requirement mailed Feb. 6, 2012”, 7 pgs.
“U.S. Appl. No. 12/491,068, Notice of Allowance mailed Nov. 28, 2011”, 17 pgs.
“U.S. Appl. No. 12/547,167, Non Final Office Action mailed Nov. 7, 2011”, 5 pgs.
“U.S. Appl. No. 12/547,167, Notice of Allowance mailed Dec. 28, 2011”, 5 pgs.
“U.S. Appl. No. 12/547,167, Response filed Nov. 8, 2011 to Non Final Office Action mailed Nov. 7, 2011”, 11 pgs.
“U.S. Appl. No. 12/557,765, Non Final Office Action mailed Mar. 9, 2012”, 16 pgs.
“U.S. Appl. No. 12/557,765, Response filed Feb. 23, 2012 to Restriction Requirement mailed Dec. 23, 2011”, 8 pgs.
“U.S. Appl. No. 12/557,765, Restriction Requirement mailed Dec. 23, 2011”, 5 pgs.
“U.S. Appl. No. 12/557,777, Non Final Office Action mailed Feb. 2, 2012”, 19 pgs.
“U.S. Appl. No. 12/557,790, Non Final Office Action mailed Dec. 22, 2011”, 11 pgs.
“U.S. Appl. No. 12/557,790, Response filed May 22, 2012 to Non Final Office Action mailed Dec. 22, 2011”, 8 pgs.
“U.S. Appl. No. 12/558,104, Non Final Office Action Mailed Feb. 3, 2012”, 17 pgs.
“U.S. Appl. No. 12/562,959 Response filed May 21, 2012 to Restriction Requirement mailed Apr. 19, 2012”, 6 pgs.
“U.S. Appl. No. 12/562,959, Restriction Requirement mailed Apr. 19, 2012”, 5 pgs.
“U.S. Appl. No. 12/583,589, Restriction Requirements mailed Feb. 6, 2012”, 8 pgs.
“U.S. Appl. No. 12/583,591, Non Final Office Action mailed Mar. 30, 2012”, 11 pgs.
“European Application Serial No. 09739237.7, Response filed Apr. 18, 2012 to Office Action mailed Jun. 20, 2011”, 4 pgs.
“International Application Serial No. PCT/US2009/002230, International Search Report mailed Jul. 3, 2009”, 6 pgs.
“International Application Serial No. PCT/US2009/002230, Written Opinion mailed Jul. 3, 2009”, 6 pgs.
“International Application Serial No. PCT/US2009/002408, Search Report mailed Aug. 13, 2009”, 7 pgs.
“International Application Serial No. PCT/US2009/002408, Written Opinion mailed Aug. 13, 2009,” 6 pgs.
“International Application Serial No. PCT/US2009/002705, International Preliminary Report on Patentability mailed”, 7 pgs.
“International Application Serial No. PCT/US2009/004766, International Report on Patentability mailed Mar. 3, 2011”, 8 pgs.
“International Application Serial No. PCT/US2009/004766, Search Report mailed Jan. 26, 2010”, 7 pgs.
“International Application Serial No. PCT/US2009/004766, Written Opinion mailed Jan. 26, 2010”, 6 pgs.
“International Application Serial No. PCT/US2009/048491, International Preliminary Report on Patentability mailed Jan. 5, 2011”, 8 pgs.
“International Application Serial No. PCT/US2009/048491, International Search Report and Written Opinion mailed Sep. 28, 2009”, 11 pgs.
“International Application Serial No. PCT/US2009/056697, International Preliminary Report on Patentability mailed Mar. 24, 2011”, 7 pgs.
“International Application Serial No. PCT/US2009/056697, Search Report mailed Nov. 25, 2009”, 4 pgs.
“International Application Serial No. PCT/US2009/056697, Written Opinion mailed Nov. 25, 2009”, 5 pgs.
“International Application Serial No. PCT/US2009/057499, Search Report mailed Feb. 8, 2010”, 8 pgs.
“International Application Serial No. PCT/US2009/057499, Written Opinion mailed Feb. 8, 2010”, 9 pgs.
“International Application Serial No. PCT/US2009/057546, International Preliminary Report on Patentability mailed Mar. 31, 2011”, 9 pgs.
“International Application Serial No. PCT/US2009/057546, Search Report mailed Dec. 30, 2009”, 8 pgs.
“International Application Serial No. PCT/US2009/057546, Written Opinion mailed Dec. 30, 2009”, 8 pgs.
“Piezo Film Sensors Technical Manual passage”, Piezo Film Sensors Technical Manual, Measurement Specialties inc. No. 1005663-1 Rev. B, XP007906698 p. 11, line 1-line 31, (Apr. 2, 1999), 89 pgs.
Jovanov, E., et al., “Patient monitoring using personal area networks of wireless intelligent sensors”, Bio-medical Sciences Instrumentation; vol. 37, XP002554091 ISSN: 0067-8856, (2001), 6 pgs.
Jovanov, E., et al., “Thermistor-based breathing sensor for circadian rhythm evaluation”, Bio-medical Sciences Instrumentation; vol. 37, XP002554092 ISSN: 0067-8856, (2001), 5 pgs.
“U.S. Appl. No. 12/557,765 , Response filed Jul. 9, 2012 to Non Final Office Action mailed Mar. 9, 2012”, 14 pgs.
“U.S. Appl. No. 12/557,765, Final Office Action mailed Aug. 2, 2012”, 17 pgs.
“U.S. Appl. No. 12/557,777, Final Office Action mailed Aug. 8, 2012”, 21 pgs.
“U.S. Appl. No. 12/557,777, Response filed Jul. 2, 2012 to Non Final Office Action mailed Feb. 2, 2012”, 13 pgs.
“U.S. Appl. No. 12/558,104, Response filed Jul. 13, 2012 to Non Final Office Action mailed Feb. 3, 2012”, 12 pgs.
“U.S. Appl. No. 12/562,669, Non Final Office Action mailed Aug. 28, 2012”, 8 pgs.
“U.S. Appl. No. 12/562,959, Non Final Office Action mailed Aug. 23, 2012”, 8 pgs.
“U.S. Appl. No. 12/583,580, Restriction Requirement mailed Dec. 17, 2012”, 7 pgs.
“U.S. Appl. No. 12/583,582, Restriction Requirement mailed Dec. 18, 2012”, 7 pgs.
“U.S. Appl. No. 12/583,588, Non Final Office Action mailed Jun. 29, 2012”, 9 pgs.
“U.S. Appl. No. 12/583,591, Final Office Action mailed Dec. 14, 2012”, 11 pgs.
“U.S. Appl. No. 12/583,591, Response filed Aug. 30, 2012 to Non Final Office Action mailed Mar. 30, 2012”, 14 pgs.
Related Publications (1)
Number Date Country
20090287265 A1 Nov 2009 US
Provisional Applications (1)
Number Date Country
61049802 May 2008 US